NeuralCipher Research overview
The text below is the source article’s original abstract under a verified reuse license. cc by
The α-synuclein seed amplification assay (SAA) is a biomarker for Parkinson's disease (PD) but requires cerebrospinal fluid. We applied a validated model to predict α-synuclein SAA+ using remotely collected data in LRRK2 G2019S carriers. VALOR-PD participants completed at-home olfactory and autonomic assessments. SAA+ probabilities for manifest and non-manifest carriers at baseline and month 36 visits were estimated. Baseline SAA+ mean probability was 0.57 (manifest) and 0.28 (non-manifest). Over three years, SAA+ mean probabilities increased in manifest (0.66, p = 0.014) and non-manifest carriers (0.38, p < 0.001), paralleling olfactory declines. Remotely collected data may be used to approximate SAA classification.
Scientific assessment
Research question
Assess the question within the original study’s scope.
Methods & sample
Check the source article for study design and sample details.
Key findings
An editorially approved findings summary is not yet published for this record.
Limitations
Generalizability, bias and clinical meaning require separate assessment.
Methods, samples and clinical conclusions are not inferred from bibliographic metadata.